TY - JOUR
T1 - Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma
T2 - a Danish population-based cohort study
AU - Juul, Maja Bech
AU - Jelicic, Jelena
AU - Anru, Pavithra Laxsen
AU - Engberg, Henriette
AU - Hammershøj Jensen, Pernille
AU - Kristensen, Helene Bjørg
AU - Baech, Joachim
AU - Clausen, Michael Roost
AU - Gang, Anne Ortved
AU - Munksgaard, Lars
AU - El-Galaly, Tarec Christoffer
AU - Frederiksen, Henrik
AU - Stauffer Larsen, Thomas
PY - 2022/9
Y1 - 2022/9
N2 - Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, comorbidities, and concerns of cardiotoxicity from doxorubicin-containing regimens. We analyzed 1009 patients aged 75 years or older and 10,090 age- and sex-matched comparisons. We aimed to evaluate long-term cardiovascular side effects in elderly patients treated with doxorubicin. Approximately, 64% of patients received doxorubicin-containing treatment. These patients had a persistently increased risk of new-onset heart failure with a hazard ratio of 1.5 and 1.7 when conditioning on survival without heart failure to 6 and 24 months, respectively. Moreover, we observed an increased risk of venous thromboembolism during the first six months following the lymphoma diagnosis. On the contrary, no difference in risk of developing ischemic heart disease or stroke following doxorubicin-containing treatment was observed.
AB - Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, comorbidities, and concerns of cardiotoxicity from doxorubicin-containing regimens. We analyzed 1009 patients aged 75 years or older and 10,090 age- and sex-matched comparisons. We aimed to evaluate long-term cardiovascular side effects in elderly patients treated with doxorubicin. Approximately, 64% of patients received doxorubicin-containing treatment. These patients had a persistently increased risk of new-onset heart failure with a hazard ratio of 1.5 and 1.7 when conditioning on survival without heart failure to 6 and 24 months, respectively. Moreover, we observed an increased risk of venous thromboembolism during the first six months following the lymphoma diagnosis. On the contrary, no difference in risk of developing ischemic heart disease or stroke following doxorubicin-containing treatment was observed.
U2 - 10.1080/10428194.2022.2064982
DO - 10.1080/10428194.2022.2064982
M3 - Journal article
C2 - 35437098
SN - 1042-8194
VL - 63
SP - 2074
EP - 2083
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -